BD Diagnostics, a division of Becton Dickinson, and Belgium's Diagenode this week announced the European launch of Diagenode's influenza A and B assay for use on the BD Max molecular testing system.
The assay is the first to be commercialized through BD's partner program, under which BD has tapped a number of third-party assay developers to create a menu of in vitro diagnostic tests for the BD Max.
The new Flu A/B primers and probes recently received a CE Mark and are validated to run on the BD Max using the BD Max RNA extraction kit RNA-3 open system reagent, which "standardizes the extraction process and offers ease of use and improved laboratory workflow," BD said in a statement.
BD unveiled the new BD Max "open" system in Europe and introduced Diagenode as the first development partner in May 2011 (PCR Insider, 5/12/2011). The platform is a six-color version of the company's real-time PCR-based BD Max system that is intended to enable labs to perform both IVD and laboratory-developed tests.
BD's partnership with Diagenode also covers assays for enteric and central nervous system diseases.
Other participants in BD's partnership program include Lab21, which is developing an assay for Aspergillus fungal infections (PCR Insider, 8/4/2011), and Italy's Biodiversity, which is working on a menu of tests for infectious agents in immunocompromised patients (PCR Insider, 8/18/2011).
BD Diagnostics has not yet named any US-based assay-development partners.